Proneura prolongata

Titan Pharmaceuticals Announces Sale of Certain ProNeura Assets

Retrieved on: 
Thursday, July 27, 2023
Agreement, Employment, Sale, Opioid use disorder, Delaware General Corporation Law, SAN, Itch, Nalmefene, Proneura prolongata, Pharmaceutical industry, Titan Pharmaceuticals, Buprenorphine, Titan

SAN FRANCISCO, July 27, 2023 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has entered into an Asset Purchase Agreement (the “Agreement”) with Fedson, Inc., a Delaware Corporation (“Fedson”), for the sale of certain ProNeura assets including Titan’s portfolio of drug addiction products, in addition to other early development programs based on the ProNeura drug delivery technology.

Key Points: 
  • SAN FRANCISCO, July 27, 2023 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has entered into an Asset Purchase Agreement (the “Agreement”) with Fedson, Inc., a Delaware Corporation (“Fedson”), for the sale of certain ProNeura assets including Titan’s portfolio of drug addiction products, in addition to other early development programs based on the ProNeura drug delivery technology.
  • Under the terms of the Agreement, Fedson will purchase the ProNeura assets from Titan for an upfront purchase price of $2 million ($1 million at closing, $1 million to be held in escrow pending completion of certain conditions) with potential milestone payments to Titan of up to $50 million on future net sales of the products.
  • Titan would also receive single digit royalties on future net sales of the products.
  • “We are pleased to announce the sale of these potentially lifesaving assets to Fedson,” stated David E. Lazar, Chief Executive Officer of Titan Pharmaceuticals.

Titan Pharmaceuticals Announces FDA Clearance of IND Application for Nalmefene Implant

Retrieved on: 
Tuesday, July 5, 2022
FDA, Opioid use disorder, Addiction medicine, Securities Act of 1933, Securities Exchange Act of 1934, National Institute, Investigational New Drug, Marketing, Titan Pharmaceuticals, OUD, SAN, Food, IND, Drug Quality and Security Act, CA, Medication, NIDA, NASDAQ, Patent, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pharmaceutical industry, Titan, Proneura prolongata

Kate Beebe DeVarney, Ph.D., President and Chief Operating Officer of Titan, commented, "FDA clearance of the IND for our ProNeura-based nalmefene implant marks an important milestone in developing a novel product that may help answer the call for long-term treatment options in addiction medicine.

Key Points: 
  • Kate Beebe DeVarney, Ph.D., President and Chief Operating Officer of Titan, commented, "FDA clearance of the IND for our ProNeura-based nalmefene implant marks an important milestone in developing a novel product that may help answer the call for long-term treatment options in addiction medicine.
  • We are very grateful for the support we received from the National Institute for Drug Addiction, or NIDA, that enabled us to meet this objective."
  • Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), based in South San Francisco, CA, is a development stage company developing proprietary therapeutics with its ProNeuralong-term, continuous drug delivery technology.
  • In December 2021, Titan commenced a process to explore and evaluate strategic alternatives to enhance shareholder value.

Titan Pharmaceuticals Announces Pricing of $5.5 Million Registered Direct and PIPE Offering Priced At-The-Market

Retrieved on: 
Wednesday, February 2, 2022
The Act, IND, S-3, Patient, Sale, SAN, NASDAQ, Attention, SEC, Medication, Special-purpose acquisition company, Regulation D, EMA, Telephone, Exercise, Form, Patent, Securities Act of 1933, SEC filing, Prospectus, Death, Marketing, Company, Health Canada, Park Avenue, Securities Exchange Act of 1934, FDA, Drug, Titan Pharmaceuticals, U.S. Securities and Exchange Commission, CA, Security (finance), Proneura prolongata, EU, Titan, Buprenorphine, Nasdaq

In a concurrent private placement, Titan has also agreed to issue and sell to the investor 1,289,796 pre-funded warrants, at the same purchase price as in the registered direct offering.

Key Points: 
  • In a concurrent private placement, Titan has also agreed to issue and sell to the investor 1,289,796 pre-funded warrants, at the same purchase price as in the registered direct offering.
  • The combined offering price of each share or pre-funded warrant and each warrant will be $1.18.
  • The aggregate gross proceeds to the Company of both offerings is expected to be approximately $5.5 million.
  • A prospectus supplement relating to the shares of common stock (or pre-funded warrants in lieu thereof) issued in the registered direct offering will be filed by Titan with the SEC.

Titan Pharmaceuticals to Explore Strategic Alternatives

Retrieved on: 
Tuesday, December 21, 2021
EMA, FDA, Titan Pharmaceuticals, Death, Acquisition, Marketing, Disclosure, IND, SAN, CA, NASDAQ, Securities Act of 1933, Company, Patent, Drug, Securities Exchange Act of 1934, Health Canada, Patient, Risk management, EU, Buprenorphine, Titan, Proneura prolongata

SOUTH SAN FRANCISCO, Calif., Dec. 21, 2021 /PRNewswire/ --Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has commenced a process to explore and evaluate strategic alternatives to enhance shareholder value.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Dec. 21, 2021 /PRNewswire/ --Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has commenced a process to explore and evaluate strategic alternatives to enhance shareholder value.
  • Potential strategic alternatives that may be explored or evaluated as part of this process include an acquisition, merger, reverse merger, other business combination, sales of assets, licensing or other strategic transactions involving the Company.
  • Titan does not expect to disclose developments with respect to this process unless and until the evaluation of strategic alternatives has been completed or the board of directors has concluded that disclosure is appropriate or legally required.
  • Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), based in South San Francisco, CA, is a development stage company developing proprietary therapeutics with its ProNeura long-term, continuous drug delivery technology.

Sustained Anti-Pruritic Effect Of Titan's TP-2021 Implant Reported Today At Neuroscience 2021

Retrieved on: 
Monday, November 8, 2021
Securities Exchange Act of 1934, University, Plasma, SAN, Kidney, NASDAQ, Department, Liver, Titan Pharmaceuticals, Society, CA, University of Washington station, Securities Act of 1933, Chronic kidney disease, Proneura prolongata, Department of Pharmacology, University College London, Drug Quality and Security Act, Mouse, Marketing, Patent, Patient, Atopic dermatitis, Executive, Pharmaceutical industry, Medical device

As previously reported , low dose TP-2021 implants had demonstrated anti-pruritic effects for up to 2 weeks in this model.

Key Points: 
  • As previously reported , low dose TP-2021 implants had demonstrated anti-pruritic effects for up to 2 weeks in this model.
  • A significant reduction in scratching behavior was maintained in mice who received the high-dose TP-2021 implant at both Day 28 and Day 56 post-implantation, compared with those that received the placebo implant, with no safety issues observed.
  • In addition, the high-dose TP-2021 implant provided sustained supra-therapeutic plasma levels of TP-2021 through Day 84.
  • "Difelikefalin (Korsuva)) intravenous injection set the guidepost for the treatment of chronic kidney disease patients undergoing hemodialysis.

Titan Announces Upcoming TP-2021 Implant Data Presentation at Neuroscience 2021

Retrieved on: 
Friday, November 5, 2021
Securities Exchange Act of 1934, Securities Act of 1933, NASDAQ, Proneura prolongata, Titan Pharmaceuticals, Marketing, Patent, Society, CA, SAN

SOUTH SAN FRANCISCO, Calif., Nov. 5, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. announced that data from continuing studies of its ProNeura-based TP-2021 implant in an established animal model of chronic pruritus will be presented at the Society for Neuroscience 2021 Meeting, being held virtually, on November 8.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 5, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. announced that data from continuing studies of its ProNeura-based TP-2021 implant in an established animal model of chronic pruritus will be presented at the Society for Neuroscience 2021 Meeting, being held virtually, on November 8.
  • Chronic pruritus is an unpleasant and often debilitating condition, resulting in the need to scratch that lasts more than 6 weeks.
  • It is a prevalent and potentially debilitating symptom associated with both cutaneous and systemic conditions.
  • Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), based in South San Francisco, CA, is a development stage company developing proprietary therapeutics with its ProNeuralong-term, continuous drug delivery technology.

Titan Pharmaceuticals Receives Funding to Develop Combination HIV Therapeutic and Contraceptive Implant for Women in Developing Countries

Retrieved on: 
Monday, October 25, 2021
Woman, Medication, Securities Act of 1933, Technology, SAN, CA, HIV, NASDAQ, Bill & Melinda Gates Foundation, Proneura prolongata, Marketing, Adolescence, Patent, Public health, Program, Health, Drug Quality and Security Act, Bill, Securities Exchange Act of 1934, Titan Pharmaceuticals, Pharmaceutical industry

"Reducing the burden of HIV, while simultaneously increasing access to contraceptive options, could have a major impact on the health of women and adolescent girls in low- and middle-income countries," said Marc Rubin, M.D., Executive Chairman of Titan.

Key Points: 
  • "Reducing the burden of HIV, while simultaneously increasing access to contraceptive options, could have a major impact on the health of women and adolescent girls in low- and middle-income countries," said Marc Rubin, M.D., Executive Chairman of Titan.
  • The continuous long-term delivery of a contraceptive/antiviral combination has the potential to have a greater public health impact in developing nations, compared with daily dosing of multiple compounds."
  • Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), based in South San Francisco, CA, is a development stage company developing proprietary therapeutics with its ProNeuralong-term, continuous drug delivery technology.
  • Such statements involve risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price.

Titan Pharmaceuticals and MUSC FRD Enter Into Research and Option License Agreement

Retrieved on: 
Tuesday, October 12, 2021
NASDAQ, Patent, FRD, Marketing, Industry, Medical school, Securities Exchange Act of 1934, Invention, Agreement, Commercialization, Securities Act of 1933, Titan Pharmaceuticals, Medical University of South Carolina, Drug Quality and Security Act, Proneura prolongata, Method, Research, MUSC, Translation, Ecosystem, Pharmaceutical industry

In exchange, FRD has granted Titan the option to acquire an exclusive worldwide, commercial license to the inventions related to MUSC's compounds.

Key Points: 
  • In exchange, FRD has granted Titan the option to acquire an exclusive worldwide, commercial license to the inventions related to MUSC's compounds.
  • Scott Davis, Ph.D., MUSC FRD's Senior Director of Innovation Support and Commercialization, commented, "We are pleased to enter into this Agreement with Titan to develop, and potentially commercialize these promising therapeutic compounds and look forward to the results of Titan's research initiatives."
  • Whether its translations involve a technology license, research collaboration, or new start-up venture, the foundation serves as a dedicated one-stop shop for advancing innovation at MUSC.
  • Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) is a development-stage biotechnology company developing proprietary therapeutics using its clinically proven ProNeuralong-term, continuous drug delivery technology.